Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2017

  • ID: 4318714
  • Report
  • 51 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Ardelyx Inc
  • OPKO Health Inc
  • PDX Pharmaceuticals LLC
  • Shield Therapeutics Plc
  • Toray Industries Inc
  • MORE
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Ardelyx Inc
  • OPKO Health Inc
  • PDX Pharmaceuticals LLC
  • Shield Therapeutics Plc
  • Toray Industries Inc
  • MORE
  1. Introduction
  2. Hyperphosphatemia In Chronic Kidney Disease - Overview
  3. Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
  15. 3SBio Inc
  16. Ardelyx Inc
  17. Daiichi Sankyo Company Ltd
  18. Medice Arzneimittel Putter GmbH & Co KG
  19. OPKO Health Inc
  20. PDX Pharmaceuticals LLC
  21. Shield Therapeutics Plc
  22. Spectrum Pharmaceuticals Inc
  23. Toray Industries Inc
  24. Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
  25. DS-2330 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. fermagate - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. niacinamide - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. PDX-004 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. PT-20 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. RDX-002 - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. sevelamer carbonate - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. Small Molecules to Target Phosphate for Hyperphosphatemia In Chronic Kidney Disease - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. SPI-014 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. tenapanor hydrochloride - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. TRK-390 - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. VS-501 - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
  78. Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
  79. Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
  80. Featured News & Press Releases
  81. Jan 06, 2017: Shield Therapeutics Provides Update on PT20
  82. May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphatemia
  83. Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
  84. Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation
  85. May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb
  86. Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014
  87. Appendix
  88. Methodology
  89. Coverage
  90. Secondary Research
  91. Primary Research
  92. Expert Panel Validation
  93. Contact Us
  94. Disclaimer
List of Tables
  1. Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc, H1
  11. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H1
  12. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company Ltd, H1
  13. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co KG, H1
  14. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H1
  15. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H1
  16. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H1
  17. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H1
  18. Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries Inc, H1
  19. Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1
  20. Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • Ardelyx Inc
  • Daiichi Sankyo Company Ltd
  • Medice Arzneimittel Putter GmbH & Co KG
  • OPKO Health Inc
  • PDX Pharmaceuticals LLC
  • Shield Therapeutics Plc
  • Spectrum Pharmaceuticals Inc
  • Toray Industries Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll